European Commission Authorizes New Biosimilar for Osteoporosis Treatment

The European Commission has granted marketing approval for Zandoriah, a biosimilar drug, for treating osteoporosis in adults. This authorization extends across the 27 EU Member States, Iceland, Liechtenstein, and Norway. The approval follows comprehensive studies confirming its comparable quality, safety, and effectiveness to the reference medicine, offering a new treatment option.